Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 67

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 67
---
 for listing (subject to official notice of issuance) on Nasdaq as of the Closing.

<div align='center'>THE MERGER AGREEMENT</div>

The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement and is incorporated by reference. The Merger Agreement has been attached to this proxy statement to provide you with information regarding its terms. It is not intended to provide any other factual information about TELO, TELI or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.

Parties to the Merger

The Agreement and Plan of Merger, dated November 20, 2025 (“Merger Agreement”), is entered into by and among TELO Pharmaceuticals, Inc., a Florida corporation, TELOPHARM Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of TELO (“Merger Sub”), and TELI. Merger Sub will merge with and into TELI, with TELI being the surviving corporation (the “Merger”).

| 38 |

Form of the Merger

Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein upon the consummation of the transactions contemplated by the Merger Agreement, Merger Sub will merge with and into TELI, with TELI continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of TELO. In the Merger, all of the issued and outstanding TELI Shares immediately prior to the Effective Time shall no longer be outstanding and shall be exchanged for and automatically converted into that certain number of fully paid and nonassessable TELIOCommon Stock as calculated in accordance with the terms of the Exchange Ratio. It is anticipated that the initial Exchange Ratio is estimated to result in TELI shareholders holding 50% of the issued and outstanding shares of TELO Common Shares.

Merger Consideration and Exchange Ratio.

At the Effective Time, each outstanding share of TELI Common Stock, will be converted into the right to receive such number of shares of common stock of TELO Common Stock, as is calculated in accordance with the Exchange Ratio, but in no instance will the amount of TELO Common Stock issued be greater than the number of outstanding TELO